DUBLIN–(BUSINESS WIRE)–The “Growth Opportunities in Synthetic Biology Enablers and Applications, Microbiome Therapeutics, Exosome-Based Drug Delivery” report has been added to ResearchAndMarkets.com’s offering.
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) focuses on advances in high throughput enzymatic DNA synthesis technologies which are being adopted across multiple lifescience and healthcare applications. The applications of gene circuits in drug discovery and therapeutics development has also been captured with innovations highlighting the use of engineered stem cells for drug discovery, and programmable cell and gene therapies amongst others. Engineered synthetic cells, microbes for antibiotic production and cell-free biosensors for environment applications are some of the other synbio related innovations covered in this issue.
The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Key Topics Covered:
Innovations in Synthetic Biology Enablers and Applications, Microbiome Therapeutics, Exosome-Based Drug Delivery
Surface Display of RNA Nanoparticles on Exosomes for Targeted siRNA Delivery
ExonanoRNA’s Value Proposition
ExonanoRNA – Investor Dashboard
Optically Reversible Protein Encapsulation in Exosomes to Control Loading and Target Inaccessible Proteins
Value Proposition of ILIAS
ILIAS – Investor Dashboard
Automated, Scalable Manufacturing for In Silico Engineered Targeted Exosomes
Mantra Bio’s Value Proposition
Mantra Bio – Investor Dashboard
Pharmacological Chaperones and Protein Stabilizing Therapeutics Targeting Protein Misfolding Disorders
Value Proposition of Protego Biopharma
Protego Biopharma- Investor Dashboard
Improved Glycoprotein Purification And Analysis Using Recombinant Prokaryotic Lectins
GlycoSeLect’s Value Proposition
GlycoSeLect – Investor Dashboard
Actinomycete Engineering Technology for Antibiotic Development with Required Bioactivity
Fermalogic’s Value Proposition
Fermalogic – Investor Dashboard
Tumor Microenvironment Sensing Targeted CAR-T Cell Therapies With Reduced Side Effects
Refuge Biotechnologies’ Value Proposition
Refuge Biotechnologies – Investor Dashboard
Engineered Synthetic Cells with Embedded Circuits to Find Utility Across Biomedical Applications
Synlife’s Value Proposition
Synlife – Investor Dashboard
Enzymatic De novo Synthesis and Gene Assembly Technology for Accurate Synthesis of complex DNA
Enzymatic DNA Synthesis with High Accuracy
Camena Bioscience – Investor Dashboard
Electrochemical Array Evaluating the Dysbiosis of Metabolites to Restore Gut Health
Premium-grade Individualized Supplements from Ixcela
Ixcela – Investor Dashboard
Gene Circuit-guided Precise Antimicrobials and In-vivo Editing of Microbiomes
Eligo Biosciences Precise Anti Bacterial Platform
Eligo Bioscience – Investor Dashboard
Portable Cell-Free Biosensors for Rapid Detection of Water Contaminants
3D-Printed Handheld Device for Water Quality Testing
Stemloop, Inc. – Investor Dashboard
Bacteriophage-based Skin Solutions Targeting Acne and Skin Irritation
Effective and Targeted Serum for Skincare
Ellis Day Skin Science – Investor Dashboard
Lab-on-Chip Based Portable DNA and Protein Synthesis Platform
Accessing Biomolecules With Desktop Bioprinter
Nuclera Nucleics Ltd – Investor Dashboard
Accurate and Cost-efficient Ultra-long Synthetic DNA Synthesis for Multiple applications
Molecular Assemblies – Investor Dashboard
Automating Long and Ultra-long DNA Printing Process
Shelf-stable Precise Synthetic Cells with for Drug Discovery and Diagnostics Applications
Calibration and Standardization Technology from Slingshot Biosciences
Slingshot Biosciences – Investor Dashboard
Scalable and Precise Cell Reprogramming Platform Using Gene Circuits for Drug Discovery and Disease Pathogenesis Modeling
Value Proposition of bit.bio
bit.bio- Investor Dashboard
Promoter-Free Gene Circuits Identifying and Killing Tumor Cells through Targeted Antibodies
Value Proposition of Southern Medical University
Key Contacts
Appendix
Criteria for Rating of Innovations–Explanation
Legal Disclaimer
Companies Mentioned
bit.bio
Camena Bioscience
Eligo Bioscience
Ellis Day Skin Science
ExonanoRNA
Fermalogic
GlycoSeLect
ILIAS
Ixcela
Mantra Bio
Molecular Assemblies
Nuclera Nucleics Ltd
Protego Biopharma
Refuge Biotechnologies
Slingshot Biosciences
Stemloop, Inc.
Synlife
For more information about this report visit https://www.researchandmarkets.com/r/wp9cgv
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
